Date, July 8 2022: Sydney.
GlyTherix has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab® monoclonal antibody therapies in gastroesophageal cancers. GEMINI, backed by the Torrey Coast Foundation, is a multi-institution collaboration of 22 scientific and clinical investigators dedicated to developing innovative new strategies to treat gastroesophageal malignancies.
Dr Sandra Ryeom, Associate Professor in the Division of Surgical Sciences in the Department of Surgery at Columbia University Irving Medical Center and the Scientific Director of GEMINI said, “GEMINI was created to accelerate the clinical trials of new therapies for gastroesophageal malignancies. We have established a network of preclinical and clinical investigators, with expertise in pre-clinical drug screening using in vitro and in vivo models, together with clinical investigators who have led Phase I clinical trials using targeted therapies in combination with immunotherapy and chemotherapy. We have exciting early data about GPC-1 expression in gastroesophageal malignancies and we look forward to testing GlyTherix’s therapies in our models”.
Dr Brad Walsh said “GEMINI is an outstanding example of scientific and clinical collaboration to accelerate novel treatments into the clinic. Our Miltuximab® therapy has proven safe in our First-in-Human clinical trial and we are looking forward to establishing its efficacy in the treatment of solid tumors. Gastroesophageal cancer is a significant unmet need and we hope that the preclinical data we obtain from this collaboration will provide the data to progress Miltuximab® into clinical trials for these patients”.
The GastroEsophageal Malignancies Investigator Network Initiative is a consortium of academic researchers and physician scientists devoted to discovering new therapies for gastroesophageal cancers. GEMINI affiliated labs can facilitate extensive pre-clinical drug screening by leveraging a substantial collection of patient derived gastroesophageal cancer organoids and multiple genetically engineered mouse models. GEMINI is funded by the Torrey Coast Foundation, and support translational research, including high risk, high reward projects.
GlyTherix Ltd is an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumours. Miltuximab® specifically targets GPC-1, a protein found in solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.
The company has a strong proprietary and Intellectual Property position covering both Miltuximab®, its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope of cure. GlyTherix has now completed a First-in-Human trial of 12 patients using Miltuximab® with no drug-related adverse events. GlyTherix is interested in partnerships or collaborations with larger biotech and pharmaceutical partners.